North America Hereditary Cancer Testing Market to 2027 - Regional Analysis and Forecasts by Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Country

The North America hereditary cancer testing market is expected to reach US$ 3,247.37 Mn in 2027 from US$ 1,255.79 Mn in 2018. The market is estimated to grow with a CAGR of 11.6% from 2019-2027.

The growth of the market is driven by factors such as, growing awareness about hereditary cancer and favorable reimbursement scenario. However, market growth is likely to slow down due to the gender gap in cancer genetic testing in the region.

Personalized medicines is a comparatively new idea that allows doctors to select medication based on a patient's hereditary profile; it is a developing area in the healthcare sector. The method not only reduces adverse side effects but also manages to produce strong results in a short period. For instance, mutations in BRCA1 and BRCA2 lead to breast cancer. However, identifying the type of variation in the breast cancer patient provides crucial information for the kind of treatment. Hence, personalized medicines allow right treatment at the right time, which reduces the mortality rate. On the back of these advantages, the personalized medicine approach is likely to create many opportunities for the hereditary cancer testing market players.

The US is expected to lead the market in the North America region to the rapidly increasing expenditure of research and development by biopharmaceutical companies. Moreover, various biopharmaceutical companies are focusing on the development of new cancer panel and direct to consumer test. Therefore, considering the factors mentioned above, growth of the market in the US is likely to contribute the most significant share in the North America region during the forecast period.

Mexico Hereditary cancer testing Market Revenue and Forecasts to 2027 (US$ Mn)

 

NORTH AMERICA HEREDITARY CANCER TESTING – MARKET SEGMENTATION

 BY DIAGNOSIS TYPE

• Biopsy
  • Blood Sample
  • Cheek Swab Sample
• Imaging

BY TECHNOLOGY

• Sequencing
• PCR
• Microarray

BY END USER

• Diagnostic Centers
• Hospital
• Clinics

Company Profiles

• Biosero Inc.
• Hologic Inc.
• Koninklijke Philips N.V.
• Quest Diagnostics Incorporated
• Myriad Genetics, Inc.
• Cancer Genetics Inc.
• Invitae Corporation
• Myogenes
• Strand Life Sciences Pvt. Ltd.
• Pathway Genomics Corporation
• CENTOGENE AG

The List of Companies

1. Biosero Inc.
2. Hologic Inc.
3. Koninklijke Philips N.V.
4. Quest Diagnostics Incorporated
5. Myriad Genetics, Inc.
6. Cancer Genetics Inc.
7. Invitae Corporation
8. Myogenes
9. Strand Life Sciences Pvt. Ltd.
10. Pathway Genomics Corporation
11. CENTOGENE AG

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America hereditary cancer testing market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the North America hereditary cancer testing market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth the North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.